Advancing the world of health

In a changing environment, technological, cultural and economic evolutions interact with new health challenges to reshape our healthcare systems. BD is at the side of all healthcare professionals, making it a unique player in the field of medical technologies. Everyday, we join forces with researchers, healthcare workers and patients all along the care pathway, helping them to meet the challenges of today and prepare for the future.

If you think you already know everything about BD’s

expertise, read no further.*

*But even after more than 120 years,we’re still learning every day.

BD, a history of care For over 120 years, BD has been accompanying healthcare professionals and patients, everywhere, at every moment.

BD has been shaping daily care for over 120 years• 120 years of innovation aimed at advancing the world of health.

• 120 years of BD products supporting all health professionals and patients, the hale and the ailing, every day, in every care setting.

• 120 years of existence, a sign of our commitment and the trust we have earned from all healthcare system players.

• 120 years of understanding and supporting changes in the world of health.

BD’s associates are committed to make a differenceOur teams interact with all parties: from physicians, laboratory biologists, nurses and pharmacists, to researchers, pharmaceutical firms, including all administrative and medical staff at public and private hospitals.Each of us helps fulfil the expectations of healthcare professionals and the needs of patients. We secure the quality and availability of the products we design and manufacture, and we offer training in their proper use to ensure optimal deployment of our solutions.

Ensuring the safety of healthcare professionals and patients is central to our strategyA pioneer in healthcare safety engineering, BD is invested in patient safety, drawing on its long experience, its expertise, and innovations. Antibiotic resistance, healthcare-associated infections, medication errors and laboratory testing errors are public health issues that BD works on every day.

Relying on our coverage, expertise and our exceptional relationship with the world of health that has lasted over 120 years, today we are helping transform our healthcare system, striving to improve its performance, relevance and safety.

€22 millionin annual R&D investments**

Antibiotic resistance• Avoiding unnecessary antibiotic treatment• Detecting and rapidly managing multidrug-resistant bacteria

Healthcare-associated infections• Confining catheter-associated and surgical-site infections• Identifying and managing patients at risk for contamination

Medication errors• Making implementation and approval of medical preparations• Securing the medication-use system, from pharmacy to ward• Controling complex IV administration schemes

Laboratory testing errors• Making reliable results quickly available to help make the right therapeutic

decision• Limiting retests and additional, unnecessary investigation

Major player in France

Worldwide coverage

70 000associates*

$1.1 billionin annual R&D investments*

$17.3 billionin turnover*

€1,209 billionin turnover

(including €738 million in exports)*

250 +250 employees each year

over the last 3 years** 63,000 hours of employee

training per year***

2 000 employees(including 1,700 in Pont-de-Claix)*

60 yearsof local activity in France

Patient safety at the heart of our strategy

Long-standing player in medical technology

1 millionprefilled syringes manufactured every day at our Pont-de-Claix

factory**

*2019 annual report **2019 company data ***2018 company data

Services de soins

Bloc opératoire

Service deréanimation

Centred’imagerieinterventionnelle

Hopital de jour

Service des urgences

Private laboratory

Hosp. center

Retail Blood collection

factory

FactoryDistribution center

Hosp.laborator

Nursing and retirement home

Patient’s home

Hosp.pharmacy

Doctor’s officeCare center

District nurse

Outpatients’ department

Pharm.industry

Research center

28thFrance ranks 28th out of 33 countries

for the death rate (8.61/100,000)1

5,600 deaths in 2015 due to infections involving 8 drugs resistant bacteria2

1 out of 201 out of 20 patients contracts an infection

during a hospital stay, which means 470,000 infected patients

and 750,000 infections per year in France3

14Around the world,

sepsis causes 20,000 deaths per day, i.e. 14 deaths per minute4

1.3 millionIn the United States, medication errors create harm in 1.3 million people every year and cause at least one death per day6

3Laboratory analytical errors affect 3 out of every 1,000 procedures5

Antibiotic resistance

Laboratory testing errors

Medication errors

Healthcare-associated infections

BD: Solutions for each step on the care pathway

65,500HIV positive

patients monitored with

BD products9

7 out of 10 vaccines

are administered by BD customers12

15 million packs of medicines stored each year

in pharmacies with BD systems7

40,000peripheral vascular

interventionswith BD products7

22,500 patients with

leukaemia and lymphomas

diagnosed and monitored8

> 135 millionsamples

drawn with BD blood collection devices (needles / collection sets)

each year7

486 millionsample tubes filled

with BD devices each year7

2.7 millionblood cultures

preparedwith BD media

and instruments each year7

> 60% of soft-tissue

biopsiesperformed with

BD products7

8 out of 10 insulin-dependent

diabeticsuse BD products10

875,000 infusions per yearperformed using BD secure administration solutions for

patients receiving home care7

Our presence in the French heathcare system

Pharmaceutical firms around the world put their trust in us1 1:

• 27 of the top 30 chose BD Medical-Pharmaceutical Systems as their partner

• More than 70 of the top 100 use our products

Research and diagnostics Administration

of care and treatments

Patient rehabilitation and monitoring

> 500 million injections or

infusions using BD products7

Interview with Nicolas ChandellierBD Managing Director for France

BD is committed to make a difference today and tomorrowOur goal is to muster our expertise to anticipate and address the health priorities set by public authorities.

Broad objectives defined by …

Tomorrow’s challenges Commitments of BD today

To promote relevant treatments and transform the health system

To guide healthcare professionals towards best practices to ensure relevance of clinical procedures

To reduce risks of exposure to infectious agents

To roll out solutions for infection prevention, better identification of infectious agents, and protection of patients and healthcare professionals

To respond to the challenges associated with chronic illnesses and their repercussions

To help improve care for patients with chronic illnesses all along their care pathways by harnessing innovation

Hello, Mr Chandellier. Today you are here to talk to us about BD. How would you describe BD in a few words?

Nicolas Chandellier: BD is a unique player in the medical technology industry from a worldwide, national, and regional perspective. For over 120 years, BD has been accompanying healthcare professionals and patients, everywhere, at every moment. Indeed, our presence all along the care pathway is what makes us unique.

How does BD show its commitment to patients?

Ensury the safety of healthcare professionals and patients is central to our strategy. We were pioneers in the enhancement of safer practices by developing solutions to protect professionals from accidental blood exposure. Today we are tackling antibiotic resistance, healthcare-associated infections, medication errors, and laboratory analytical errors. These are public health issues that affect everyone, healthcare professional and patients alike.

How is BD at the side of every healthcare system player?

Our products are literally used everywhere, by everybody. By patients themselves, for diabetic treatment, by nurses, doctors, biologists, and others. Whether the patient is receiving care at home, the doctor’s office, or the hospital, our solutions may be adapted to any setting and are there to help professionals as they perform their most routine acts. This coverage affords us a complete vision of the healthcare system and the needs of all parties, but it also shoulders us with the responsibility to offer innovations that anticipate these needs and meet them.

How are employees at the heart of BD strategy?

Our growth goes hand in hand with a major training initiative, relying especially on our in-house university,

which delivers unique course offerings adapted to each

of our employees. Each year, 63,000 hours are spent on

training within our company in France.

BD also offers a range of occupational specialities providing many opportunities for career changes. Furthermore, our company also helps its talents progress

through career development programmes that match

their aspirations for advancement.

We are recognized for our commitment to invest in human

resources. This commitment plays out in training and

career development programs, as well as quality of life at

work, which is a priority for us. Our company agreements

bear witness to this. They reflect our resolve to innovate in

matters of employment by offering our staff more choices

and flexibility, while allowing them to strike a better

balance between their personal and professional lives.

How would you illustrate inclusion at BD?

Inclusion and diversity together constitute one of the

pillars of our company culture.

In the name of diversity, BD has taken a stand to champion

gender equality by supporting the advancement of

women’s careers, no matter the positions involved.

BD is also an active member of various networks advocating

greater diversity, including the Women’s Initiative Network

(WIN).

BD promotes the employment of disabled individuals. Our rate of employment of assocates with disabilities is far

higher than that legally required of us,

exceeding 7% for over three years now. We have also developed around fifteen partnerships with local, regional, and national associations to promote and support workforce integration for the unemployed.

What does BD’s environmental commitment look like?

Very concrete actions. For example, the Grenoble site has set up 12 recycling channels, absorbing 70% of its waste. Over the last five years, €1.8 million of investments have gone towards sustainable development.

  ‘Improving patient safety means helping

to make the healthcare system more efficient.’

“ We learn and improve every day. ”

VALUESOUR STANDARDS OF BEHAVIOR

We do what is right

We are all accountable

We thrive on innovation and demand quality

We learn and improve every day

We help each other be great

What predictions might BD make tomorrow’s challenges?

I am convinced that medical devices will play a structuring role in the development of the healthcare system. Today already, technology provides possibilities unimaginable only ten years ago and compels us to completely reconsider our mode of operation. Some procedures previously only performed in operating rooms can now be carried out in doctor’s offices and may no longer even require surgery. This compels us to totally reassess the ways private practices and hospitals interact. In this regard, medical devices may help the system stop thinking in terms of places of treatment and start thinking in terms of care pathways.Moreover, it is the ambition of the authorities to develop these paths, as clearly shown by the French Ma Santé 2022 agenda, alongside other objectives closely aligned with our own.

Treatment relevance and patient involvement are two priorities we could mention that strike a chord with us and strengthen our resolve to follow through with our commitments. We are ready to contribute to this transformation, especially since our positioning within the healthcare system makes us a natural partner to help usher in these changes. We already work with all healthcare players and share the same concern: to meet patients’ needs.

in the hospital in the laboratory

at home at the pharmacy

R & D PRODUCTIONSUPPORT

for implementing our solutions

DISTRIBUTION

ENSURING PATIENT SAFETY

RESPONSIBLE FOR ALL STAGES OF THE PRODUCT LIFE CYCLE

‘Medical devices help counter

healthcare system compartmentalization.’

Interview with Nicolas ChandellierBD Managing Director for France

For over 120 years, BD has been accompaying healthcare professionals and patients, everywhere, at every moment.

1. OECD. Stemming the superbug tide: just a few dollars more. Paris: OECD Publishing; 2018.

2. Coignard B. Burden of multidrug-resistant bacteria infections, France, 2012. Study report, June 2015. Saint-Maurice: Institut de Veille Sanitaire; 2015.

3. Michel P, Minodier C, Moty-Monnereau C, Lathelize M, Domecq S, Chaleix M, Kret M, Roberts T, Nitaro L, Bru-Sonnet R, et al. Les évènements indésirables graves dans les établissements de santé : fréquence, évitement et acceptabilité [Serious adverse event in healthcare establishments: frequency, prevention, and acceptability]. DREES; 2011. No.761.

4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-10

5. Carraro P., Plebani M. Errors in a Stat Laboratory: types and frequencies 10 years later. Clin. Chem. 2007;53:7;1338-42

6. WHO launches global effort to halve medication-related errors in 5 years. WHO. 2017 Mar 29. News release.

7. Company data for fiscal year 2019.

8. - Maladies auto-immunes [Autoimmune diseases]. Paris: INSERM; [modified 2018 Jul 13; accessed 2019 Oct 18]. https://www.inserm.fr/information-en-sante/dossiers-information/maladies-auto-immunes. - Cancer Environnement. Les hémopathies malignes de l’adulte [Malignant blood diseases in adults]. Lyon: Centre Léon Bérard; 2019 [accessed 2019 Oct 18]. https://www.cancer-environnement.fr/283-Hemopathies-malignes-de-ladulte.ce.aspx. - Les hémopathies malignes se chronicisent en France [Malignant blood diseases are becoming chronic in France] Paris La Défense: Celgene; 2017 [accessed 2019 Oct 18]. https://www.celgene.fr/les-hemopathies-malignes-se-chronicisent-en-france/#. - Les chiffres des lymphomes et leucémies en France [Figures for lymphomas and leukaemia in France]. Villejuif: Fondation ARC; 2013 [accessed 2019 Oct 18]. https://www.fondation-arc.org/actualites/les-chiffres-des-lymphomes-et-leucemies-en-france. - https://www.santepubliquefrance.fr/docs/estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en france-metropolitaine-entre-1990-et-2018-volume-2-hemopathies-maligne [Estimated national cancer incidence and mortality in metropolitan France between 1990 and 2018] Santé publique France, 2019 [accessed 2020 Feb 25].

9. Roncier C. Le VIH/sida en France en 2018. [HIV/AIDS in France in 2018]. Paris: PISTES; 2018 [accessed 2020 Feb 25]. http://vih.org/dossier/vihsida-en-france-en-2018.

10. IMS data, February 2019.

11. IQVIA-based analysis & BD Internal systems (SAP ECC, SAP Legacy, Tracis, Nodum)—2016 update.

12. Cabinet TMC 2019

References

Advancing the world of health

BD, the BD logo, BD Laboratory Consulting Services, BD Microtainer, and BD Vacutainer are registered trademarks of Becton, Dickinson and Company. ©2019 BD and subsidiaries All rights reserved. XEUR-0002-18WEU261

BD - 11, rue Aristide Bergès - ZI des Iles - BP4 - 38801 - Le Pont de Claix CedexTél : 04 76 68 36 36

bd.com/fr

Doc

umen

t pr

inte

d on

100

% re

cycl

ed p

aper